Ophthotech (OPHT) Upgraded to C by TheStreet
Ophthotech (NASDAQ:OPHT) was upgraded by equities researchers at TheStreet from an “e+” rating to a “c” rating in a research report issued on Thursday.
A number of other brokerages have also issued reports on OPHT. Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 target price for the company in a research report on Monday, November 13th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Ophthotech in a report on Thursday, September 21st. Finally, ValuEngine raised shares of Ophthotech from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Twelve research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $8.31.
Shares of Ophthotech (NASDAQ OPHT) opened at $3.20 on Thursday. Ophthotech has a twelve month low of $2.24 and a twelve month high of $40.34. The firm has a market cap of $113.16, a PE ratio of 2.00 and a beta of 1.56.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp and related companies with MarketBeat.com's FREE daily email newsletter.